Immunic Net Income
| IMUX Stock | USD 0.62 0.03 5.08% |
As of the 8th of February, Immunic retains the Market Risk Adjusted Performance of (0.13), standard deviation of 4.56, and Risk Adjusted Performance of (0.02). Immunic technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices.
Immunic's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Immunic's valuation are provided below:We have found one hundred twenty available fundamental trends for Immunic, which can be analyzed and compared to other ratios and to its competitors. All investors should make sure to confirm all of Immunic regular market performance against the performance between 2010 and 2026 to make sure the company can sustain itself down the road. Market Cap is likely to drop to about 48.7 M in 2026. Enterprise Value is likely to rise to about (66.2 M) in 2026 This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. | Last Reported | Projected for Next Year | ||
| Net Loss | -90.5 M | -85.9 M | |
| Net Loss | -90.5 M | -95 M | |
| Net Loss | -108.4 M | -102.9 M | |
| Net Loss | (0.90) | (0.95) | |
| Net Income Per E B T | 0.90 | 0.80 |
Immunic | Net Income | Build AI portfolio with Immunic Stock |
The evolution of Net Income for Immunic provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Immunic compares to historical norms and industry peers.
Latest Immunic's Net Income Growth Pattern
Below is the plot of the Net Income of Immunic over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Immunic financial statement analysis. It represents the amount of money remaining after all of Immunic operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Immunic's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Immunic's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (100.51 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Immunic Net Income Regression Statistics
| Arithmetic Mean | (55,761,281) | |
| Coefficient Of Variation | (63.57) | |
| Mean Deviation | 29,310,835 | |
| Median | (47,667,000) | |
| Standard Deviation | 35,448,928 | |
| Sample Variance | 1256.6T | |
| Range | 114.5M | |
| R-Value | (0.87) | |
| Mean Square Error | 317.6T | |
| R-Squared | 0.76 | |
| Slope | (6,132,108) | |
| Total Sum of Squares | 20106T |
Immunic Net Income History
Other Fundumenentals of Immunic
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Immunic Net Income component correlations
Immunic Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Immunic is extremely important. It helps to project a fair market value of Immunic Stock properly, considering its historical fundamentals such as Net Income. Since Immunic's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Immunic's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Immunic's interrelated accounts and indicators.
Click cells to compare fundamentals
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Immunic. Market participants price Immunic higher when confident in its future expansion prospects. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Immunic assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Immunic's market price often diverges from its book value, the accounting figure shown on Immunic's balance sheet. Smart investors calculate Immunic's intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Since Immunic's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Please note, there is a significant difference between Immunic's value and its price as these two are different measures arrived at by different means. Investors typically determine if Immunic is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immunic's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Immunic 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Immunic's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Immunic.
| 11/10/2025 |
| 02/08/2026 |
If you would invest 0.00 in Immunic on November 10, 2025 and sell it all today you would earn a total of 0.00 from holding Immunic or generate 0.0% return on investment in Immunic over 90 days. Immunic is related to or competes with Pmv Pharmaceuticals, Relmada Therapeutics, Acrivon Therapeutics, Lite Strategy, Vaxart, Tscan Therapeutics, and Biomea Fusion. Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies fo... More
Immunic Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Immunic's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Immunic upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.06) | |||
| Maximum Drawdown | 21.44 | |||
| Value At Risk | (6.58) | |||
| Potential Upside | 9.43 |
Immunic Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Immunic's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Immunic's standard deviation. In reality, there are many statistical measures that can use Immunic historical prices to predict the future Immunic's volatility.| Risk Adjusted Performance | (0.02) | |||
| Jensen Alpha | (0.31) | |||
| Total Risk Alpha | (0.65) | |||
| Treynor Ratio | (0.14) |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Immunic's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Immunic February 8, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.02) | |||
| Market Risk Adjusted Performance | (0.13) | |||
| Mean Deviation | 3.59 | |||
| Coefficient Of Variation | (2,444) | |||
| Standard Deviation | 4.56 | |||
| Variance | 20.77 | |||
| Information Ratio | (0.06) | |||
| Jensen Alpha | (0.31) | |||
| Total Risk Alpha | (0.65) | |||
| Treynor Ratio | (0.14) | |||
| Maximum Drawdown | 21.44 | |||
| Value At Risk | (6.58) | |||
| Potential Upside | 9.43 | |||
| Skewness | 0.3912 | |||
| Kurtosis | 0.048 |
Immunic Backtested Returns
Immunic holds Efficiency (Sharpe) Ratio of -0.0516, which attests that the entity had a -0.0516 % return per unit of risk over the last 3 months. Immunic exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please check out Immunic's Market Risk Adjusted Performance of (0.13), standard deviation of 4.56, and Risk Adjusted Performance of (0.02) to validate the risk estimate we provide. The company retains a Market Volatility (i.e., Beta) of 1.43, which attests to a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Immunic will likely underperform. At this point, Immunic has a negative expected return of -0.23%. Please make sure to check out Immunic's jensen alpha, skewness, as well as the relationship between the Skewness and day typical price , to decide if Immunic performance from the past will be repeated at some point in the near future.
Auto-correlation | -0.32 |
Poor reverse predictability
Immunic has poor reverse predictability. Overlapping area represents the amount of predictability between Immunic time series from 10th of November 2025 to 25th of December 2025 and 25th of December 2025 to 8th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Immunic price movement. The serial correlation of -0.32 indicates that nearly 32.0% of current Immunic price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.32 | |
| Spearman Rank Test | -0.09 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Immunic Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Immunic reported net income of (100.51 Million). This is 129.45% lower than that of the Biotechnology sector and 243.49% lower than that of the Health Care industry. The net income for all United States stocks is 117.6% higher than that of the company.
Immunic Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Immunic's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Immunic could also be used in its relative valuation, which is a method of valuing Immunic by comparing valuation metrics of similar companies.Immunic is currently under evaluation in net income category among its peers.
Immunic Current Valuation Drivers
We derive many important indicators used in calculating different scores of Immunic from analyzing Immunic's financial statements. These drivers represent accounts that assess Immunic's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Immunic's important valuation drivers and their relationship over time.
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Market Cap | 74.9M | 239.5M | 226.4M | 44.5M | 51.2M | 48.7M | |
| Enterprise Value | 46.1M | 113.0M | 140.5M | (60.6M) | (69.7M) | (66.2M) |
Immunic Institutional Holders
Institutional Holdings refers to the ownership stake in Immunic that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Immunic's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Immunic's value.| Shares | Ikarian Capital, Llc | 2025-06-30 | 914.2 K | Ghisallo Capital Management Llc | 2025-06-30 | 835 K | Blackrock Inc | 2025-06-30 | 698.7 K | Rtw Investments, Llc | 2025-06-30 | 402.1 K | Ubs Group Ag | 2025-06-30 | 376.1 K | State Street Corp | 2025-06-30 | 331.9 K | Northern Trust Corp | 2025-06-30 | 258.3 K | Boothbay Fund Management, Llc | 2025-06-30 | 240.9 K | Renaissance Technologies Corp | 2025-06-30 | 132.2 K | Aberdeen Group Plc | 2025-06-30 | 8.2 M | Bvf Inc | 2025-06-30 | 7.7 M |
Immunic Fundamentals
| Return On Equity | -3.98 | ||||
| Return On Asset | -1.25 | ||||
| Current Valuation | 39.64 M | ||||
| Shares Outstanding | 120.28 M | ||||
| Shares Owned By Insiders | 1.07 % | ||||
| Shares Owned By Institutions | 49.00 % | ||||
| Number Of Shares Shorted | 7.09 M | ||||
| Price To Earning | (6.65) X | ||||
| Price To Book | 7.05 X | ||||
| EBITDA | (97.92 M) | ||||
| Net Income | (100.51 M) | ||||
| Cash And Equivalents | 72.77 M | ||||
| Cash Per Share | 1.85 X | ||||
| Total Debt | 1 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 7.53 X | ||||
| Book Value Per Share | 0.11 X | ||||
| Cash Flow From Operations | (84.77 M) | ||||
| Short Ratio | 4.19 X | ||||
| Earnings Per Share | (0.80) X | ||||
| Price To Earnings To Growth | (0.03) X | ||||
| Target Price | 5.38 | ||||
| Number Of Employees | 90 | ||||
| Beta | 1.59 | ||||
| Market Capitalization | 74.58 M | ||||
| Total Asset | 40.87 M | ||||
| Retained Earnings | (511.4 M) | ||||
| Working Capital | 17.16 M | ||||
| Current Asset | 32.33 M | ||||
| Current Liabilities | 4.73 M | ||||
| Net Asset | 40.87 M |
About Immunic Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Immunic's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Immunic using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Immunic based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Immunic Stock Analysis
When running Immunic's price analysis, check to measure Immunic's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunic is operating at the current time. Most of Immunic's value examination focuses on studying past and present price action to predict the probability of Immunic's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunic's price. Additionally, you may evaluate how the addition of Immunic to your portfolios can decrease your overall portfolio volatility.